Phase II study of Cetuximab with mFOLFOX6 treatment in patients with previously untreated Rectal cancer - Phase II study of Cetuximab with mFOLFOX6 treatment in patients with previously untreated Rectal cancer (CR study in SHIGA)

PO FMPC (Future Medicine Promoting Consortium)0 个研究点目标入组 25 人开始时间: 2013年5月23日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) History of serious drug hypersensitivity (2) Women who are pregnant,or wish to become pregnant or men who expect babies (3) Severe infectious disease (38degrees or higher) (4) Serious complications (5) Remarkably abnormal ECG,Clinically significant heart disease (6) Gastrointestinal ulceration or bleeding (7) Serious watery diarrhea (8) Uncontrolable pleural effusion or ascites requiring treatment (9) Cases with brain metastases or cases to doubt metastasis to brain from clinical manifestations (10) Current or previous (within the last 6months) history of GI perforation (11) Previous history of thrombosis,cerebra infarction,pulmonary infarction,hemoptysis (more than 2.5ml) and interstitial pneumonia (12) Cases were operated within 28days before entry (Except for inserting central venous catheters and reservoir) (13) Evidence of congenital bleeding diathesis or coagulopathy (14) Ongoing treatment with anticoagulant (15) Cases have active double cancer (disease free period is within five years) (16) Continuous systemic administration of corticosteroids (17) Patients judged inapproprite for this study by physicians

发起方

PO FMPC (Future Medicine Promoting Consortium)